Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI
In this week’s View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Arrhythmias and Clinical EP, Cardio-Oncology, COVID-19 Hub, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Lipid Metabolism, Nonstatins, Acute Heart Failure, Acute Coronary Syndromes
Keywords: EaglesEyeView, Anthracyclines, Cardio-oncology, Cardiotoxicity, Heart Failure, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, COVID-19, Cholesterol, HDL, Myocardial Infarction, Secondary Prevention
